logo-loader
viewMotif Bio PLC

Timing of General Meeting and Circular

/**/ h1{margin-top:2.65pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;font-size:18.0pt;font-family:"Arial","sans-serif";font-weight:normal;}h2{margin:0cm;margin-bottom:.0001pt;font-size:16.0pt;font-family:"Arial","sans-serif";font-weight:bold;}h3{margin:0cm;margin-bottom:.0001pt;font-size:16.0pt;font-family:"Arial","sans-serif";font-weight:normal;}h4{margin-top:2.85pt;margin-right:0cm;margin-bottom:0cm;margin-left:34.75pt;margin-bottom:.0001pt;font-size:13.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h5{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:5.0pt;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h6{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:5.0pt;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:bold;font-div:italic;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue } visited{ color: #3EBBF0 } .ak{size:612.0pt 792.0pt;margin:42.55pt 42.55pt 42.55pt 42.55pt;}div.ak{}p.az{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: center}p.ba{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify}p.bb{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; text-align: justify}span.au{color:red}p.bc{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold}p.bd{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-right:-.85pt;text-align:justify}span.as{color:black}table.be{width:517.4pt;margin-left:-5.4pt;border-collapse:collapse} td.ap{width:254.7pt;padding:0cm 5.4pt 0cm 5.4pt}p.bf{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-right: -.85pt; text-align: justify}td.an{width:241.1pt;padding:0cm 5.4pt 0cm 5.4pt}p.bg{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-right: -.85pt; text-align: right}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";}span.al{color:windowtext; text-decoration:none} /**/
RNS Number : 5969Q
Motif Bio PLC
21 October 2019
 

21 October 2019

 

Motif Bio plc

("Motif Bio", or "the Company")

 

Timing of General Meeting and Circular

 

Motif Bio plc (AIM/NASDAQ: MTFB) today announced that the Circular mentioned in the Company's 2 October 2019 press release, is expected to be posted to shareholders this week. The Circular will include details of the Resolutions which shareholders will be asked to approve at the General Meeting.

 

All defined terms in this announcement shall have the same meaning as described in the Company's announcement of 2 October 2019.

 

The person responsible for the release of this announcement on behalf of Motif Bio plc is Jonathan Gold, Interim Chief Financial Officer.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

For further information, please contact:

 

Motif Bio plc

[email protected]

Graham Lumsden (Chief Executive Officer)

 

 

 

SP Angel Corporate Finance LLP (NOMAD & BROKER)

+44 (0)20 3470 0470

David Hignell/Caroline Rowe (Corporate Finance)

Vadim Alexandre/Abigail Wayne (Sales & Broking)

 

 

 

Walbrook PR Ltd. (UK FINANCIAL PR & IR)

+44 (0)20 7933 8780

Paul McManus/Lianne Cawthorne

[email protected]

 

 

MC Services AG (EUROPEAN IR)

+49 (0)89 210 2280

Raimund Gabriel

[email protected]

 

 

Forward-Looking Statements

This press release contains forward-looking statements. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Motif Bio's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Motif Bio believes that these factors include, but are not limited to, (i) Motif Bio's ability to obtain shareholder approval in connection with the Proposed Restructuring, (ii) Motif Bio's ability to execute the Proposed Capital Raise and Proposed Restructuring (iii) the timing, progress and the results of clinical trials for Motif Bio's product candidates, (iv) the timing, scope or likelihood of regulatory filings and approvals for Motif Bio's product candidates, (v) Motif Bio's ability to successfully commercialise its product candidates, (vi) Motif Bio's ability to effectively market any product candidates that receive regulatory approval, (vii) Motif Bio's commercialisation, marketing and manufacturing capabilities and strategy, (viii) Motif Bio's expectation regarding the safety and efficacy of its product candidates, (ix) the potential clinical utility and benefits of Motif Bio's product candidates, (x) Motif Bio's ability to advance its product candidates through various stages of development, especially through pivotal safety and efficacy trials, (xi) Motif Bio's estimates regarding the potential market opportunity for its product candidates, (xii) Motif Bio's ability to raise additional capital to sustain its operations and pursue its strategy and (xiii) the factors discussed in the section entitled "Risk Factors" in Motif Bio's Annual Report on Form 20-F filed with the SEC on April 15, 2019, which is available on the SEC's web site, www.sec.gov. Additionally, there can be no assurance that Motif Bio will regain compliance with Nasdaq rules or maintain its ADS listing on Nasdaq. Motif Bio undertakes no obligation to update or revise any forward-looking statements.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCUAVORKNARUAA

Quick facts: Motif Bio PLC

Price: 0.4825

Market: AIM
Market Cap: £2.34 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: AfriTin Mining produces first concentrate from Uis mine

Headlines from the Proactive UK newsroom. AfriTin Mining (LON:ATM) has produced is first tin concentrate from the Uis mine in Namibia. The miner has also signed an offtake deal with a Thai group.  BlueRock Diamonds (LON:BRD) has sold a fifth diamond this year for more than US$50,000....

on 19/8/19

RNS

Holding(s) in Company

1 day, 11 hours ago

Directorate Changes

3 days, 17 hours ago

Result of General Meeting

1 week, 1 day ago

Settlement Agreement

1 week, 4 days ago

Holding(s) in Company

3 weeks, 4 days ago

Holding(s) in Company

4 weeks ago